Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure (Q44567982)

4 December 2017

title

Cholinergic stimulation with pyridostigmine reduces ventricular arrhythmia and enhances heart rate variability in heart failure (English)

1 reference

4 December 2017

main subject

heart rate variability

0 references

1 reference

1 reference

3

Luis E Rohde

1 reference

4 December 2017

Alice Behling

1

1 reference

4 December 2017

Ruy S Moraes

2

1 reference

4 December 2017

Elton L Ferlin

4

1 reference

4 December 2017

Antonio C L Nóbrega

5

1 reference

4 December 2017

Jorge P Ribeiro

6

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 September 2003

1 reference

4 December 2017

published in

American Heart Journal

1 reference

4 December 2017

volume

146

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

494-500

1 reference

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Autonomic pathophysiology in heart failure patients. Sympathetic-cholinergic interrelations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Prospective study of heart rate variability and mortality in chronic heart failure: results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Independent and incremental prognostic value of heart rate variability in patients with chronic heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Arrhythmia risk stratification in idiopathic dilated cardiomyopathy based on echocardiography and 12-lead, signal-averaged, and 24-hour holter electrocardiography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Electrical stability of acutely ischemic myocardium. Influences of heart rate and vagal stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Termination of ventricular tachycardia by an increase in cardiac vagal drive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Enhancement of heart rate variability by cholinergic stimulation with pyridostigmine in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Sympathetic nervous system representation in time and frequency domain indices of heart rate variability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Preserved left ventricular systolic and diastolic function in normoalbuminuric insulin-dependent diabetic patients with glomerular hyperfiltration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Effect of partial arrhythmia suppression with amiodarone on heart rate variability of patients with congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Bradycardia produced by pyridostigmine and physostigmine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Cholinergic stimulation with pyridostigmine, hemodynamic and echocardiographic analysis in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Cholinergic stimulation with pyridostigmine blunts the cardiac responses to mental stress.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Exercise stress testing in healthy subjects during cholinergic stimulation after a single dose of pyridostigmine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Pyridostigmine blunts the increases in myocardial oxygen demand elicited by the stimulation of the central nervous system in anesthetized rats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Spontaneous variability of ventricular arrhythmias in patients at increased risk for sudden death after acute myocardial infarction: consecutive ambulatory electrocardiographic recordings of 88 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Parasympathetic control of cardiac sympathetic activity: normal ventricular function versus congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Muscarinic receptor stimulation with edrophonium hydrochloride does not elevate ventricular fibrillation thresholds in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Scopolamine improves autonomic balance in advanced congestive heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Do increases in markers of vagal activity imply protection from sudden death? The case of scopolamine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Cardiac vagal efferent activity and heart period in the carotid sinus reflex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

Relationship of heart rate variability to parasympathetic effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-8703%2803%2900319-3

10.1016/S0002-8703(03)00319-3

7 January 2021

Identifiers

DOI

1 reference

4 December 2017

1 reference